Publications by authors named "M Meggendorfer"
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.
View Article and Find Full Text PDFBackground: The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE) thrombotic events as well as bleeding episodes.
Methods: Data from 246 consecutive MF patients were analyzed.
Article Synopsis
- B-acute lymphoblastic leukaemia (B-ALL) is a blood cancer characterized by the uncontrolled growth of immature B lymphoblasts due to issues in the blood-forming system.
- Genetic testing has become crucial for accurately classifying B-ALL and determining patient risk, as traditional methods often failed to assign about 30% of cases.
- Recent advancements in genomic technologies, like whole-genome sequencing and optical genome mapping, are improving diagnosis and treatment, offering new insights into personalized care and more accurate prognostic markers for patients with B-ALL.
Article Synopsis
- Myeloproliferative neoplasms (MPN) are diverse blood disorders with abnormal blood cell production and a risk of progressing to severe phases, such as blast phase.
- The WHO 2022 categorization recognizes distinct MPNs like chronic myeloid leukemia and others, but diagnosing these conditions can be tricky due to overlapping features and missing clinical information.
- A new model based on 12 genetic markers has been created to help accurately classify MPN patients; it shows that genetic mutations can change as the disease progresses, emphasizing the need for enhanced genetic testing at both diagnosis and during disease advancement.